Cargando…
The co‐chaperone p23 promotes prostate cancer motility and metastasis
Prostate cancer is an androgen receptor (AR)‐dependent malignancy at initiation and progression, therefore hormone therapy is the primary line of systemic treatment. Despite initial disease regression, tumours inevitably recur and progress to an advanced castration‐resistant state a major feature of...
Autores principales: | Querol Cano, Laia, Lavery, Derek N., Sin, Soraya, Spanjaard, Emma, Brooke, Greg N., Tilman, Jessica D., Abroaf, Ahmed, Gaughan, Luke, Robson, Craig N., Heer, Rakesh, Mauri, Francesco, de Rooij, Johan, Driouch, Keltouma, Bevan, Charlotte L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4510206/ https://www.ncbi.nlm.nih.gov/pubmed/25241147 http://dx.doi.org/10.1016/j.molonc.2014.08.014 |
Ejemplares similares
-
Molecular Functions of WWOX Potentially Involved in Cancer Development
por: Taouis, Karim, et al.
Publicado: (2021) -
Engineering prostate cancer in vitro: what does it take?
por: Buskin, Adriana, et al.
Publicado: (2023) -
Kindlin‐1 drives early steps of breast cancer metastasis
por: Bonin, Florian, et al.
Publicado: (2022) -
Engineered repressors are potent inhibitors of androgen receptor activity
por: Brooke, Greg N., et al.
Publicado: (2014) -
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
por: Cizkova, Magdalena, et al.
Publicado: (2012)